Table 3.
The Distributions of SLC1A1, SLC6A1, FAM131B, GPLD1, F2, GABRG2, GABRA1, and CACNG5 SNPs in Patients with Generalized Epilepsy (GE) and Healthy Controls
| Gene | rs number | Model | GEP % | Control % | P-value |
|---|---|---|---|---|---|
| SLC1A1 | rs10815018 | AA/AG/GG | 64.7/28.2/7.1 | 51/39.2/9.8 | 0.016 |
| AA/(AG+GG) | 64.7/35.3 | 51/49 | 0.004 | ||
| (AA+AG)/GG | 92.9/7.1 | 90.2/9.8 | 0.31 | ||
| SLC6A1 | rs10510403 | AA/AG/GG | 65.7/27.9/6.4 | 63/31.6/5.4 | 0.66 |
| AA/(AG+GG) | 65.7/34.3 | 63/37 | 0.55 | ||
| (AA+AG)/GG | 93.6/6.4 | 94.6/5.4 | 0.65 | ||
| FAM131B | rs4236482 | GG/GA/AA | 61.6/31.4/7 | 62.5/33.8/3.7 | 0.28 |
| GG/(AG+AA) | 61.6/38.4 | 62.5/37.5 | 0.84 | ||
| (GG+AG)/AA | 93/7 | 96.3/3.7 | 0.12 | ||
| GPLD1 | rs1126617 | CC/CT/TT | 56.7/40.9/2.3 | 58.5/34.1/7.4 | 0.029 |
| CC/(CT+TT) | 56.7/43.3 | 58.5/41.5 | 0.70 | ||
| (CT+CC)/TT | 97.7/2.3 | 92.6/7.4 | 0.015 | ||
| rs2076317 | AA/AG/GG | 45.4/47.7/7 | 48.5/40.5/11 | 0.17 | |
| AA/(AG+GG) | 45.4/54.6 | 48.5/51.5 | 0.51 | ||
| (AA+AG)/GG | 93/7 | 89/11 | 0.14 | ||
| F2 | rs1799963 | GG/AG/AA | 94.8/4.7/0.6 | 97/3/0 | 0.24 |
| GG/(AG+AA) | 94.8/5.2 | 97/3 | 0.23 | ||
| (GG+AG)/AA | 99.4/0.6 | 100/0 | 0.16 | ||
| GABRG2 | rs209337 | CC/CA/AA | 89.5/9.9/0.6 | 93.3/6.7/0 | 0.16 |
| CC/(CA+AA) | 10.5/99.4 | 6.7/100 | 0.15 | ||
| (CC+CA)/AA | 90.1/9.9 | 93.3/6.7 | 0.15 | ||
| GABRA1 | rs2279020 | AA/GA/GG | 33.7/50/16.3 | 34.3/48.5/17.2 | 0.94 |
| AA/(GA+GG) | 33.7/66.3 | 34.3/65.7 | 0.89 | ||
| (AA+GA)/GG | 83.7/16.3 | 82.8/17.2 | 0.80 | ||
| CACNG5 | rs740805 | AA/AG/GG | 88.8/11.2/0 | 87.8/11.2/1 | 0.25 |
| AA/(AG+GG) | 88.8/11.2 | 87.8/12.2 | 0.75 | ||
| (AA+AG)/GG | 100/0 | 99/1 | 0.098 |